- Home
- SERV vs LIMN Comparison
SERV vs LIMN Comparison
Compare SERV & LIMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- LIMN
- Stock Information
- Founded
- SERV 2017
- LIMN 2018
- Country
- SERV United States
- LIMN United States
- Employees
- SERV N/A
- LIMN N/A
- Industry
- SERV Industrial Specialties
- LIMN
- Sector
- SERV Consumer Discretionary
- LIMN
- Exchange
- SERV Nasdaq
- LIMN NYSE
- Market Cap
- SERV 609.5M
- LIMN 623.8M
- IPO Year
- SERV N/A
- LIMN N/A
- Fundamental
- Price
- SERV $10.01
- LIMN $5.93
- Analyst Decision
- SERV Strong Buy
- LIMN
- Analyst Count
- SERV 4
- LIMN 0
- Target Price
- SERV $17.00
- LIMN N/A
- AVG Volume (30 Days)
- SERV 5.3M
- LIMN 987.0K
- Earning Date
- SERV 08-12-2025
- LIMN 01-01-0001
- Dividend Yield
- SERV N/A
- LIMN N/A
- EPS Growth
- SERV N/A
- LIMN N/A
- EPS
- SERV N/A
- LIMN N/A
- Revenue
- SERV $1,306,237.00
- LIMN N/A
- Revenue This Year
- SERV $284.61
- LIMN N/A
- Revenue Next Year
- SERV $580.91
- LIMN N/A
- P/E Ratio
- SERV N/A
- LIMN N/A
- Revenue Growth
- SERV 17.26
- LIMN N/A
- 52 Week Low
- SERV $4.66
- LIMN $4.40
- 52 Week High
- SERV $24.35
- LIMN $33.66
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- LIMN N/A
- Support Level
- SERV N/A
- LIMN N/A
- Resistance Level
- SERV N/A
- LIMN N/A
- Average True Range (ATR)
- SERV 0.00
- LIMN 0.00
- MACD
- SERV 0.00
- LIMN 0.00
- Stochastic Oscillator
- SERV 0.00
- LIMN 0.00
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.